Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Growing evidence suggests that nonalcoholic fatty liver disease is associated with an increased risk of cardiovascular disease beyond that conferred by established risk factors.

[1]  J. Everhart,et al.  Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. , 2009, Gastroenterology.

[2]  M. Chonchol,et al.  Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. , 2009, Seminars in thrombosis and hemostasis.

[3]  G. Marchesini,et al.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? , 2008, Diabetologia.

[4]  R. D'Agostino,et al.  Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Ross J. Harris,et al.  Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[6]  N. Lundbom,et al.  Postprandial lipemia associates with liver fat content. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[8]  J. Browning.  Statins and hepatic steatosis: Perspectives from the Dallas Heart Study , 2006, Hepatology.

[9]  D. Houlihan,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[10]  G. Marchesini,et al.  Obesity-associated liver disease. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  E. Bonora,et al.  Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. , 2010, Journal of hepatology.

[12]  Hirokazu Takahashi,et al.  High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH , 2007, Journal of Gastroenterology.

[13]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[14]  X. Papademetris,et al.  The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome , 2007, Proceedings of the National Academy of Sciences.

[15]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[16]  D. Jacobs,et al.  Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. , 2006, European heart journal.

[17]  R. Xu,et al.  Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study , 2008, The American Journal of Gastroenterology.

[18]  A. Mora,et al.  A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance , 2008, Science.

[19]  G. Zoppini,et al.  Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. , 2004, Diabetes care.

[20]  P. Scifo,et al.  Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver , 2007, Hepatology.

[21]  W. Goessling,et al.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. , 2008, Gastroenterology.

[22]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[23]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[24]  M. Abouzari,et al.  Liver: an alarm for the heart? , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[25]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[26]  C. Day,et al.  Benefits of lifestyle modification in NAFLD , 2007, Gut.

[27]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[28]  G. Targher,et al.  Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. , 2007, Journal of hepatology.

[29]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[30]  A. Kotronen,et al.  Fatty Liver: A Novel Component of the Metabolic Syndrome , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  G. Marchesini,et al.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease , 2005, Hepatology.

[33]  D. Kim,et al.  Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. , 2009, Atherosclerosis.

[34]  T. Lehtimäki,et al.  Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. , 2006, American journal of physiology. Endocrinology and metabolism.

[35]  S. Goland,et al.  Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment , 2006, Journal of clinical gastroenterology.

[36]  Norbert Stefan,et al.  Causes and metabolic consequences of Fatty liver. , 2008, Endocrine reviews.

[37]  G. Lippi,et al.  NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men , 2008, Obesity.

[38]  A. Feldstein,et al.  Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis , 2008, The American Journal of Gastroenterology.

[39]  S. Bischoff,et al.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. , 2008, The Journal of nutrition.

[40]  J. Cercueil,et al.  Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. , 2009, The Journal of clinical endocrinology and metabolism.

[41]  C. Day.  From fat to inflammation. , 2006, Gastroenterology.

[42]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[43]  H. Concin,et al.  γ-Glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality: An Epidemiological Investigation in a Cohort of 163 944 Austrian Adults , 2005, Circulation.

[44]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[45]  J. Takeda,et al.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. , 2007, World journal of gastroenterology.

[46]  K. Yun,et al.  Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. , 2009, Atherosclerosis.

[47]  L. N. Valenti,et al.  Carotid artery intima-media thickness in nonalcoholic fatty liver disease. , 2008, The American journal of medicine.

[48]  L. Bouter,et al.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. , 2007, Atherosclerosis.

[49]  K. Petersen,et al.  Disordered lipid metabolism and the pathogenesis of insulin resistance. , 2007, Physiological reviews.

[50]  Fang-Chi Hsu,et al.  Hepatic Steatosis and Subclinical Cardiovascular Disease in a Cohort Enriched for Type 2 Diabetes: The Diabetes Heart Study , 2008, The American Journal of Gastroenterology.

[51]  E. Bonora,et al.  [Metabolic syndrome and cardiovascular diseases]. , 2008, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[52]  D. Schwartz,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[53]  H. Lo,et al.  Sonographic fatty liver, overweight and ischemic heart disease. , 2005, World journal of gastroenterology.

[54]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[55]  G. Musso,et al.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.

[56]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[57]  Henry Völzke,et al.  Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‐glutamyl transpeptidase levels , 2009, Hepatology.

[58]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[59]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[60]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[61]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[62]  G. Porto,et al.  World J Gastroenterol , 2010 .

[63]  James G Wright,et al.  The development of a comorbidity index with physical function as the outcome. , 2005, Journal of clinical epidemiology.

[64]  C. Day,et al.  Non-alcoholic fatty liver disease: the mist gradually clears. , 2008, Journal of hepatology.

[65]  Emilio Ros,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[66]  G. Targher,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[67]  ChristofKessler,et al.  Hepatic steatosis is associated with an increased risk of carotid atherosclerosis , 2005 .

[68]  J. Flier,et al.  The adipocyte as an active participant in energy balance and metabolism. , 2007, Gastroenterology.

[69]  S. Sookoian,et al.  Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. , 2008, Journal of hepatology.

[70]  S. Wannamethee,et al.  The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. , 2008, Atherosclerosis.